



1Fw
\$

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnleach@synnleach.com
www.synnleach.com

June 21, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John M. Stewart
Bradley J. Steeves
Karl Vernes

Group Art Unit: 1614

Examiner: N.Y.A.

Confirmation No: 7296

Application No.: 10/716,314

Filing Date: November 18, 2003

For: Paralytic Peptide for Use in Neuromuscular
Therapy

(Attorney Docket No: P26,473-A USA)

I hereby certify that this correspondence, along with any other papers indicated as being enclosed, is being deposited with the United States Postal Services, as first class mail, postage prepaid, in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on June 21, 20056.

Janet M. Karrmann

Mail Stop: Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)(3)

Sir:

It is requested respectfully that the information identified on the enclosed Form PTO-1449 (Modified) be made of record and considered with respect to the above-referenced patent application. A copy of each item of information identified on the Form and required by 37 C.F.R. §1.98(a)(2) is enclosed. The Examiner is requested to indicate that each item on the

06/28/2006 MBIZUNES 00000060 195425 10716314

01 FC:1806 180.00 DA

enclosed Form PTO-1449 (Modified) has been considered by initialing and dating the enclosed Form and returning a copy of same to the undersigned.

Identification of information on the attached Form, or in this statement, is not an admission that such information is prior art to the invention claimed in the present application or that such information is in an analogous art area.

This Information Disclosure Statement is filed before a first Office Action on the merits. However, if the first Office Action happens to cross in the mail with the submission of this Information Disclosure Statement, the Patent Office is hereby authorized to charge the amount of \$180.00 pursuant to the fee required under 37 C.F.R. §1.17(p) to Deposit Account Number 19-5425.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Marc S. Segal', is written over the typed name.

Marc S. Segal, Esquire
Registration No. 40,163

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
Telephone (215) 923-4466
Facsimile (215) 923-2189

FORM PTO-1449 (MODIFIED)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.	10/716,314
FILING DATE	November 18, 2003
FIRST NAMED INVENTOR	J. Stewart
ART UNIT	1614
CONFIRMATION NO.	7296
EXAMINER NAME	N.Y.A.
ATTORNEY DOCKET NO.	P26,473-A USA

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	NAME
	AA	5,424,286	June 13, 1995	Eng

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	COUNTRY
	AB	JP 10-236963	September 8, 1998	JP

OTHER PUBLICATIONS

	AC	Cai, Z., et al. "Solution Structure of BmBKTx1, a New BK _{Ca} ¹ Channel Blocker from the Chinese Scorpion <i>Buthus martensi Karsch.</i> "; Biochemistry, Vol. 43, No. 13, pp. 3764-3771 (2004).
	AD	Christenbury, P. "A Study of the Ecology of Blarina Brevicauda in North Carolina and of the Effect of Shrew Toxin on the Liver and Kidneys of Mice."; A thesis submitted to the Graduate Faculty of Wake Forest College in partial fulfillment of the requirements for the degree of Master of Arts in the Department of Biology; (August 1966).
	AE	Dekker, E., et al. "The epithelial calcium channels, TRPV5 and TRPV6: from identification towards regulation."; Cell Calcium 33, pp. 497-507 (2003).
	AF	Dufton, M. "Venomous Mammals"; Pharmac. Ther. Vol. 53, pp. 199-215 (1992).
	AG	Ellis, S., et al. "Properties of a Toxin From the Salivary Gland of the XShrew, Blarina Brevicauda"; The Journal of Pharmacology & Experimental Therapeutics; Vol. 114, No. 2, pp. 127-137 (1955).
	AH	GenCore version 5.1.7, pages 3-4 (Result 5)
	AI	George, S., et al. "Blarina brevicauda"; Mammalian Species, No. 261, pp. 1-9, 3 figs (1986).
	AJ	Kita, M., et al. "Blarina toxin, a mammalian lethal venom from the short-tailed shrew <i>Blarina brevicauda</i> : Isolation and characterization." PNAS, Vol. 101, No. 20, pp. 7542-7547 (2004).
	AK	Lecchi, P., et al. "The Structure of Synenkephalin (Pro-Enkephalin ₁₋₇₃) Is Dictated by Three Disulfide Bridges"; Biochemical and Biophysical Research Communications, Vol. 232, No. 3, pp. 800-805 (1997).
	AL	Martin, I. "Venom of the Short-Tailed Shrew (<i>Blarina Brevicauda</i>) as an Insect Immobilizing Agent"; Journal of Mammalogy, Vol. 62, No. 1, pp. 189-192 (1978).
	AM	Montell, C. "The Venerable Inveterate Invertebrate TRP Channels"; Cell Calcium 33, pp. 409-417 ((2003).

	BA	Mount Allison University "Potent Peptide Paralytic Agent", Version 1 (June 2003).
	BB	Mount Allison University "Potent Peptide Paralytic Agent" Version 2 (July 2003).
	BC	Peng, J-B, et al. "CaT1 Expression Correlates with Tumor Grade in Prostate Cancer"; Biochemical and Biophysical Research Communication, Vol 282, pp: 729-734 (2001).
	BD	Peng, J-B, et al. "Human Calcium Transport Protein CaT1"; Biochemical and Biophysical Research Communications, Vol. 278, No. 2, pp: 326-332 (2000).
	BE	Phol, M., et al. "Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard"; The Journal of Biological Chemistry, Vol. 273, No. 16, pp: 9778-9784 (1998).
	BF	Pucek, M. "Chemistry and Pharmacology of Insectivore Venoms"; Chapter 3 of Venomous Animals and Their Venoms edited by W. Bucher, Academic Press, New York – London, pp: 43-50 (1968).
	BG	Smart, P. "Shrew Saliva Spells Relief? Prof. Jack Stewart makes breakthrough medical discovery"; The Argosy (January 16, 2003).
	BH	"The venom of the shrew may be in the new Botox"; National Post, Science Section (Biochemistry) (December 20, 2002).
	BI	Tomasi, T. "Function of Venom in the Short-Tailed Shrew Blarina brevicauda"; Journal of Mammalogy, Vol. 59, No. 4, pp: 852-854 (1978)
	BJ	Zhuang, L., et al. "Calcium-Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and is Aberrantly Expressed in Human Malignancies"; Laboratory Investigation, Vol. 82, No. 12, pp: 1755-1764 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (MODIFIED)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.	10/716,314
FILING DATE	November 18, 2003
FIRST NAMED INVENTOR	J. Stewart
ART UNIT	1614
CONFIRMATION NO.	7296
EXAMINER NAME	N.Y.A.
ATTORNEY DOCKET NO.	P26,473-A USA

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	NAME
	AA	5,424,286	June 13, 1995	Eng

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NO.	PUBLICATION DATE	COUNTRY
	AB	JP 10-236963	September 8, 1998	JP

OTHER PUBLICATIONS

	AC	Cai, Z., et al. "Solution Structure of BmBKTx1, a New BK _{Ca} Channel Blocker from the Chinese Scorpion <i>Buthus martensi Karsch.</i> "; Biochemistry, Vol. 43, No. 13, pp. 3764-3771 (2004).
	AD	Christenbury, P. "A Study of the Ecology of Blarina Brevicauda in North Carolina and of the Effect of Shrew Toxin on the Liver and Kidneys of Mice."; A thesis submitted to the Graduate Faculty of Wake Forest College in partial fulfillment of the requirements for the degree of Master of Arts in the Department of Biology; (August 1966).
	AE	Dekker, E., et al. "The epithelial calcium channels, TRPV5 and TRPV6: from identification towards regulation."; Cell Calcium 33, pp. 497-507 (2003).
	AF	Dufton, M. "Venomous Mammals"; Pharmac. Ther. Vol. 53, pp. 199-215 (1992).
	AG	Ellis, S., et al. "Properties of a Toxin From the Salivary Gland of the XShrew, Blarina Brevicauda"; The Journal of Pharmacology & Experimental Therapeutics; Vol. 114, No. 2, pp. 127-137 (1955).
	AH	GenCore version 5.1.7, pages 3-4 (Result 5)
	AI	George, S., et al. "Blarina brevicauda"; Mammalian Species, No. 261, pp. 1-9, 3 figs (1986).
	AJ	Kita, M., et al. "Blarina toxin, a mammalian lethal venom from the short-tailed shrew <i>Blarina brevicauda</i> : Isolation and characterization." PNAS, Vol. 101, No. 20, pp. 7542-7547 (2004).
	AK	Lecchi, P., et al. "The Structure of Synenkephalin (Pro-Enkephalin ₁₋₇₃) Is Dictated by Three Disulfide Bridges"; Biochemical and Biophysical Research Communications, Vol. 232, No. 3, pp. 800-805 (1997).
	AL	Martin, I. "Venom of the Short-Tailed Shrew (<i>Blarina Brevicauda</i>) as an Insect Immobilizing Agent"; Journal of Mammalogy, Vol. 62, No. 1, pp. 189-192 (1978).
	AM	Montell, C. "The Venerable Inveterate Invertebrate TRP Channels"; Cell Calcium 33, pp. 409-417 ((2003).

	BA	Mount Allison University "Potent Peptide Paralytic Agent", Version 1 (June 2003).
	BB	Mount Allison University "Potent Peptide Paralytic Agent" Version 2 (July 2003).
	BC	Peng, J-B, et al. "CaT1 Expression Correlates with Tumor Grade in Prostate Cancer"; Biochemical and Biophysical Research Communication, Vol 282, pp: 729-734 (2001).
	BD	Peng, J-B, et al. "Human Calcium Transport Protein CaT1"; Biochemical and Biophysical Research Communications, Vol. 278, No. 2, pp: 326-332 (2000).
	BE	Phol, M., et al. "Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard"; The Journal of Biological Chemistry, Vol. 273, No. 16, pp: 9778-9784 (1998).
	BF	Pucek, M. "Chemistry and Pharmacology of Insectivore Venoms"; Chapter 3 of Venomous Animals and Their Venoms edited by W. Bucher, Academic Press, New York - London, pp: 43-50 (1968).
	BG	Smart, P. "Shrew Saliva Spells Relief? Prof. Jack Stewart makes breakthrough medical discovery"; The Argosy (January 16, 2003).
	BH	"The venom of the shrew may be in the new Botox"; National Post, Science Section (Biochemistry) (December 20, 2002).
	BI	Tomasi, T. "Function of Venom in the Short-Tailed Shrew Blarina brevicauda"; Journal of Mammalogy, Vol. 59, No. 4, pp: 852-854 (1978)
	BJ	Zhuang, L., et al. "Calcium-Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and is Aberrantly Expressed in Human Malignancies"; Laboratory Investigation, Vol. 82, No. 12, pp: 1755-1764 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.